- Home
- MLCO vs MLYS Comparison
MLCO vs MLYS Comparison
Compare MLCO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLCO | MLYS |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2006 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MLCO | MLYS |
|---|---|---|
| Price | $6.10 | $29.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $9.42 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $4.40 | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.55 | $8.79 |
| 52 Week High | $10.15 | $47.65 |
Technical Indicators
Market Signals| Indicator | MLCO | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 45.18 |
| Support Level | $5.88 | $26.85 |
| Resistance Level | $6.54 | $32.21 |
| Average True Range (ATR) | 0.32 | 1.46 |
| MACD | 0.07 | 0.27 |
| Stochastic Oscillator | 78.26 | 46.46 |
Price Performance
Historical ComparisonAbout MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.